Patents Assigned to Pfizer Inc.
  • Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
    Publication number: 20040176387
    Abstract: A method of treating a patient suffering from peripheral vascular disease, peripheral neuropathies, or autonomic neuropathies by administering a cGMP PDE5 inhibitor such as sildenafil. The method is particularly applicable to patients suffering from diabetic foot ulcers, Raynaud's Phenomenon, CREST Syndrome, erythromatosis, rheumatoid diseases, diabetic retinopathies and onychiomycosis. According to the present invention, a cGMP PDE5 inhibitor may be administered as a prophylactic to patients predisposed to develop a peripheral vascular disease, peripheral neuropathy or autonomic neuropathy.
    Type: Application
    Filed: March 10, 2004
    Publication date: September 9, 2004
    Applicant: Pfizer Inc
    Inventor: Ralph E. Wood
  • Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use
    Publication number: 20040176431
    Abstract: Aminothiazole compounds substituted with sulfur-containing groups are represented by the Formula (I), and their pharmaceutically acceptable salts, prodrugs, active metabolites, and pharmaceutically acceptable salts of said metabolites are described.
    Type: Application
    Filed: February 11, 2004
    Publication date: September 9, 2004
    Applicant: Pfizer, Inc.
    Inventors: Wesley K.M. Chong, Shao Song Chu, Rohit K. Duvadie, James Na, Lana Schaffer, Yi Yang, Lin Li
  • Controlled release by extrusion of solid amorphous dispersions of drugs
    Publication number: 20040175428
    Abstract: Controlled release dosage forms for low solubility drugs are disclosed wherein an amorphous solid dispersion of the drug is coated with a non-dissolving and non-eroding coating that controls the influx of water to the core so as to cause extrusion of a portion of the core, as well as a method of treating a disease or disorder comprising administering such dosage form to a person.
    Type: Application
    Filed: March 11, 2004
    Publication date: September 9, 2004
    Applicant: Pfizer Inc.
    Inventors: Leah E. Appel, William J. Curatolo, Scott M. Herbig, James A.S. Nightingale, Avinash G. Thombre
  • Prevention of loss and restoration of bone mass by certain prostaglandin agonists
    Publication number: 20040176461
    Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
    Type: Application
    Filed: August 29, 2003
    Publication date: September 9, 2004
    Applicant: Pfizer Inc
    Inventors: Kimberly O. Cameron, Hua Z. Ke, Bruce A. Lefker, Robert L. Rosati, David D. Thompson
  • Glucocorticoid receptor modulators
    Publication number: 20040176595
    Abstract: The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonist and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds.
    Type: Application
    Filed: November 25, 2003
    Publication date: September 9, 2004
    Applicant: Pfizer, Inc.
    Inventors: Robert L. Dow, Kevin K. Liu, Bradley P. Morgan, Andrew G. Swick
  • Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors
    Publication number: 20040176390
    Abstract: Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: February 20, 2004
    Publication date: September 9, 2004
    Applicant: Pfizer Inc
    Inventors: Laura C. Blumberg, Michael J. Munchhof, Andrei Shavnya
  • Combination therapies for the stimulation of bone growth
    Publication number: 20040176423
    Abstract: This invention relates to pharmaceutical combinations of a prostaglandin agonist and a HMG-CoA reductase inhibitor, methods of using such combinations and kits containing such combinations. The pharmaceutical combinations, methods and kits are useful to enhance bone formation in mammals, including humans.
    Type: Application
    Filed: March 16, 2004
    Publication date: September 9, 2004
    Applicant: Pfizer Inc.
    Inventor: Vishwas M. Paralkar
  • 6-Azauracil derivatives as thyroid receptor ligands
    Patent number: 6787652
    Abstract: The present invention provides novel compounds of the Formula I and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R1 to R8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure are also provided.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: September 7, 2004
    Assignee: Pfizer, Inc.
    Inventors: Robert L. Dow, Yuan-Ching P. Chiang, Kimberly G. Estep
  • Substituted N-cycloalkyl-N-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
    Patent number: 6787570
    Abstract: The invention relates to substituted N-Alkyl/Alkenyl/Cycloalkyl/Heterocycyl N-Aryl/Heteroaryl tertiary-Heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery disease. Preferred tertiary-heteroalkylamine compounds are substituted N-cycloalkyl N-benzyl aminoalcohols.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: September 7, 2004
    Assignee: Pfizer, Inc.
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Deborah A. Mischke, Emily J. Reinhard, Barry L. Parnas, Melvin L. Rueppel
  • Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
    Patent number: 6787563
    Abstract: The present invention relates to substituted N-(cyclopropylmethyl)azacycloalkanes of the following formula (I): in which, independently, R1 is hydrogen or halogen, R2 is hydrogen or halogen and X is methylene or ethylene, their salts, the pharmaceutical compositions containing them, their use as antidiarrhoeal medicaments and methods for their preparation.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: September 7, 2004
    Assignee: Pfizer Inc.
    Inventor: Henry Jacobelli
  • Neospora vaccine
    Patent number: 6787146
    Abstract: The present invention provides an homogenate prepared from cells of Neospora, and vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: September 7, 2004
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: David A. Brake, Manuel Campos
  • VEGF responsive cell-based assay for determining VEGF bioactivity
    Patent number: 6787323
    Abstract: A VEGF responsive cell-based assay for determining VEGF bioactivity is disclosed. The assay utilizes established signal transduction pathways in a method for determining VEGF bioactivity in a sample.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: September 7, 2004
    Assignee: Pfizer Inc
    Inventors: Brian Lee Batley, Tawny Kay Dahring, Sotirios K. Karathanasis, Robert Lee Panek, Ye Edward Tian
  • Citrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
    Patent number: 6787549
    Abstract: The present invention is directed to the citrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene: and pharmaceutical compositions thereof. The present invention is also directed to the various forms of the citrate salt, particularly its hydrate and its anhydrous/nearly anhydrous polymorph. The invention is also directed to processes for preparation of these citrate salt forms.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: September 7, 2004
    Assignee: Pfizer Inc.
    Inventors: Phillip J. Johnson, Peter R. Rose, Glenn R. Williams, Lewin T. Wint
  • Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
    Publication number: 20040171798
    Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1
    Type: Application
    Filed: February 17, 2004
    Publication date: September 2, 2004
    Applicant: Pfizer Inc
    Inventors: Thomas V. Magee, Anthony Marfat, Robert J. Chambers
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
    Publication number: 20040171842
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: December 4, 2003
    Publication date: September 2, 2004
    Applicant: Pfizer Inc
    Inventors: David John Kucera, Robert William Scott
  • Substituted aromatic ethers as inhibitors of glycine transport
    Patent number: 6784299
    Abstract: This invention relates to a series of substituted aromatic ethers of the formula I wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: August 31, 2004
    Assignee: Pfizer Inc.
    Inventor: John A. Lowe, III
  • Pharmaceutically active compounds
    Patent number: 6784185
    Abstract: Compounds of general formula I: or pharmaceutically or veterinarily acceptable salts, solvates, polymorphs or pro-drugs thereof wherein: wherein R1, R2, R3, R4, X and A have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: August 31, 2004
    Assignee: Pfizer Inc.
    Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Mark Ian Kemp
  • Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
    Publication number: 20040167131
    Abstract: This invention discloses amino acid derivatives which display inhibitory effects on the serine protease factor Xa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, methods for the preparation of the compounds, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.
    Type: Application
    Filed: September 11, 2003
    Publication date: August 26, 2004
    Applicant: Pfizer Inc.
    Inventors: Gary Louis Bolton, Kevin James Filipski, Jeffrey Thomas Kohrt, Frances La, Daniele Marie Leonard
  • Pharmaceutical combination
    Publication number: 20040167153
    Abstract: The present invention relates to a combination of a selective PDE4 inhibitor, as defined herein, and an adrenergic &bgr;2 receptor agonist for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.
    Type: Application
    Filed: December 16, 2003
    Publication date: August 26, 2004
    Applicant: Pfizer Inc
    Inventor: Michael Yeadon
  • Palatable controlled-released formulations for companion animals
    Publication number: 20040166157
    Abstract: The invention pertains to chewable controlled-release multiparticulate pharmaceutical compositions for companion animals and method of making same.
    Type: Application
    Filed: February 20, 2004
    Publication date: August 26, 2004
    Applicant: Pfizer Inc
    Inventor: Avinash G. Thombre